1. Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Iran 2. Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Iran 4. Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Iran
Proprotein convertase subtilisin/kexin type 9 (pcsk9) is a serine protease and a secreted protein which increases cholesterol levels in plasma via inducing degradation of low-density lipoprotein receptor (ldlr). some studies have reported that pcsk9 levels increase in hypothyroidism. cluster of differentiation 36 (cd36) is a member of a family of cell surface proteins in many cells. cd36 involves in regulation of lipid metabolism by facilitating cellular uptake of fatty acids and participating in triglyceride storage. it has been suggested that pcsk9 regulates cd36 in some tissues.
Data and serum levels of tsh, ft4 and pcsk9 and expression level of cd36 on monocytes from 20 new untreated patients with sh and 20 age- sex- and bmi-matched controls were analyzed in a cross-sectional study. quantification of cd36 expression on monocytes was done by flow cytometry. then the relationships between these parameters were examined.
Pcsk9 was significantly higher in patients. cd36 expression was lower in the patient group than in controls, but this difference was not significant. there was no significant relationship between pcsk9 and cd36.
Currently, pcsk9 inhibitors are used to reduce blood cholesterol levels as drugs. if it will be proven that pcsk9 can reduce the level of cd36, taking these drugs may have unwanted side effects. this study showed that there is no relationship between pcsk9 and cd36 in subclinical hypothyroidism and pcsk9 antibodies can still be used as an effective way to treat hypercholesterolemia.
Subclinical hypothyroidism, proprotein convertase subtilisin kexin type 9, cluster of differentiatio